Synapse Medicine Initiates Multi-Site Implementation Study with Leading U.S Hospitals

Synapse Medicine  

PR98160

 

NEW YORK, Oct. 6, 2022, /PRNewswire=KYODO JBN/ --

 

• Synapse Medicine clinical decision support technology analyzes drug-related

risks based on each patient's clinical characteristics and will be studied for

its impact on inpatient pharmacist efficacy and efficiency.

• The Synapse Medicine medication reconciliation tool will be deployed through

an integration with the hospitals' current EPIC EHR workflow.

• The study also has potential to provide improvements to medication regimen

appropriateness which helps reduce risk of ADEs in hospital and after discharge.

 

Synapse Medicine, a leader in intelligent medication decision technology,

announced today it has initiated a clinical study with Brigham and Women's

Hospital, Boston, MA and the Vanderbilt University Medical Center, Nashville,

TN to measure the benefits and efficacy of its clinical decision support

solution and its medication reconciliation software in a hospital setting. The

principal investigator is Dr. Jeffrey L. Schnipper, MD, MPH, MHM, of the

Brigham's Division of General Internal Medicine and Primary Care and the

Hospital Medicine Unit, and Professor of Medicine at Harvard Medical School.

 

The study, "Effect of Synapse Medicine Decision Support on Inpatient Pharmacist

Efficacy and Efficiency: A Hybrid Type 2 Implementation Study," engages

hospital pharmacists at two study sites who round with general medicine service

teams and approve inpatient medications. Participants will use Synapse Medicine

point-of-care tools to analyze drug-related risks and optimize medication

appropriateness. They will also perform medication reconciliation for newly

admitted patients. The study will measure the usability of Synapse Medicine

AI-driven clinical decision support and medication reconciliation tools

quantitatively and qualitatively to determine their impact.

 

Leveraging real-time data for medication regimen appropriateness

 

Healthcare systems have long been challenged by the task of drug regimen

optimization, a critical aspect in a patient's continuity of care. An

inaccurate medication history or inappropriate drug therapy can burden

care-providers' efficiency, delay treatment, put patients at risk for

preventable adverse drug events (ADEs), and contribute to higher readmission

rates. Hospital-related ADEs are frequent and dangerous, and their management

has been estimated to cost US$28 billion annually.1

 

"Hospitalized patients often come to us on suboptimal medication regimens,

especially too many medications. But we also encounter medications that react

with each other, incorrect doses based on their kidney function, or medications

that are inappropriate based on their many medical conditions," said Schnipper.

"At the same time that we are treating patients' acute medical conditions, we

also owe it to them to address these longer-standing medication issues and make

sure we don't introduce any new medication-related problems before they return

home."

 

Technology-based clinical decision support creates efficiencies and improves

patient outcomes

 

"Optimizing a patient's medication regimen can be a time-consuming and

complicated process, but it is fundamental to ensuring patient safety and

therapeutic success," shared Dr. Clement Goehrs, Synapse Medicine CEO and

Co-Founder. "Collaborating with Brigham and Women's Hospital and Vanderbilt

University Medical Center allows us to demonstrate how our medication decision

support technology improves accuracy and streamlines processes creating more

time for actual patient care and bringing value to all stakeholders."

 

Synapse Medicine solutions are built on a technology platform that uses machine

learning and natural language processing. It combines real-time drug knowledge

with clinical data to detect potential medication risks and discrepancies that

can lead to ADEs. The suite of clinical decision support tools enables

healthcare professionals to provide enhanced personalized care for patients.

The study will evaluate the prescription analysis, drug monograph and

medication reconciliation solutions for efficiency and accuracy.

 

About Synapse Medicine

 

At Synapse Medicine, we believe in medication success, and are dedicated to

making it possible for everyone.

 

To achieve this goal, we have built an extensive, global medication knowledge

base using algorithms to ensure the most reliable, up-to-date data. On the

front-end, Synapse Medicine provides a SaaS platform and UI components that are

used to prescribe, dispense, and manage medications across the entire patient

journey.

 

At Synapse Medicine, we are working with world-leading hospitals and digital

health companies in the United States, Europe and Japan to transform today's

medication regimens into tomorrow's medication success.

 

1.        Weiss, A.J., Freeman, W.J., Heslin, K.C. and Barrett, M.L., 2018. Adverse

drug events in US hospitals, 2010 versus 2014. HCUP Statistical Brief, 234.

 

press@synapse-medicine.com, +33 (0)5 56 35 50 87

 

Logo - https://mma.prnewswire.com/media/1914883/Synapse_Medicine_Logo.jpg

 

SOURCE: Synapse Medicine  

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中